Precision Radiotherapy Enabled by Molecular MRI
This is a research study to determine if a novel molecular magnetic resonance imaging (MRI) technique, called amide proton transfer (APT) imaging, is useful in identifying the most aggressive areas of tumor needed for radiotherapy of brain tumors.
| Condition(s) | Brain Cancer |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This is a research study to determine if a novel molecular magnetic resonance imaging (MRI) technique, called amide proton transfer (APT) imaging, is useful in identifying the most aggressive areas of tumor needed for radiotherapy of brain tumors. |
| Who can participate | Inclusion Criteria: * Histologic confirmation of glioblastoma or grade 4 astrocytoma * Age \>18 * KPS at least 60 * Patients must have normal organ and marrow function as defined below: * leukocytes \>3,000/mcL * absolute neutrophil count \>1,500/mcL * platelets \>100,000/mcL * total bilirubin within normal institutional limits * AST(SGOT)/ALT(SGPT) \<2.5 * institutional upper limit of normal * creatinine within normal institutional limits OR creatinine clearance \>60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal. * Patients of child-bearing potential (male or female) must practice adequate contraception due to possible harmful effects of radiation therapy on an unborn child. * Ability to understand and the willingness to sign a written informed consent docu |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Locations | Baltimore, Maryland, United States |
| Start date | 2026-04-29 |
| NCT ID | NCT07512154 |
| Official listing | https://clinicaltrials.gov/study/NCT07512154 |